Fisher & Paykel Healthcare Investor Day presentation

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)
Fisher & Paykel Healthcare provides Investor Day presentation
Auckland, New Zealand, 26 May 2022
Fisher & Paykel Healthcare Corporation Limited attaches a copy of its presentation to analysts
and investors from the Investor Day held today at its Auckland campus.
There is no new material information contained within the presentation.
The presentation is also now available on the company’s website at
http://www.fphcare.co.nz/investor/presentations.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive
sleep apnea. The company’s products are sold in over 120 countries worldwide. For more
information about the company, visit our website www.fphcare.com.
Ends
Media & Investor Contacts:
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 (0) 21 713 911
Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073

---

Andrew Somervell – Vice President
Products and Technology
Better Products:
An R&D Overview

Fisher & Paykel Healthcare Investor Day 2022
Agenda
10:00amWelcomeAndy Niccol & Vandna Patel
General Manager - Respiratory Humidification &
Product Development Engineer
10:05amOur AspirationLewis Gradon & Lyndal YorkManaging Director / CEO & CFO
10:25am
Better Products: an R&D
overview
Andrew SomervellVice president - Products & Technology
11:00am
Breakout sessions
Airvo3
Optiflow- Trace & Switch
Chris Crone & Sam Frame
Winston Fong
General Manager & Marketing Manager – AirvoGroup
Vice president - Surgical Technologies
12:00pmLunch Break / Site tour & Product expo
1:00pm
Breakout Sessions
Airvo3
Optiflow- Trace & Switch
Chris Crone & Sam Frame
Winston Fong
General Manager & Marketing Manager – AirvoGroup
Vice president - Surgical Technologies
2:00pm Q&AAll presenters
2:30pmThank you / Close

Lewis Gradon – Managing Director / CEO
Lyndal York - CFO
Our aspiration

OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.
Our aspiration –prior to COVID-19

OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.
COVID-19 has
accelerated placement
of hospital hardware
and given us the
opportunity to advance
our longer-term plans.
The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being
indicative of levels of revenue or profitability in the short term.
Our aspiration -now

OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.
COVID-19 has
accelerated placement
of hospital hardware
and given us the
opportunity to advance
our longer-term plans.
The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being
indicative of levels of revenue or profitability in the short term.
Our aspiration -now

OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.
COVID-19 has
accelerated placement
of hospital hardware
and given us the
opportunity to advance
our longer-term plans.
The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being
indicative of levels of revenue or profitability in the short term.
Our aspiration -now

OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.
COVID-19 has
accelerated placement
of hospital hardware
and given us the
opportunity to advance
our longer-term plans.
The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being
indicative of levels of revenue or profitability in the short term.
Our aspiration -now

Long term margin targets
•Long term gross margin and
operating margin targets
remain unchanged
•Freight rates expected to
remain elevated in the near
term
Accelerated investment in:
•R&D – Surgical technologies,
Home respiratory support
•Anesthesia sales team
Long Term Gross Margin target
GROSS MARGIN
0%
10%
20%
30%
40%
50%
60%
70%
201720182019202020212022
OPERATING (EBIT) MARGIN
Long Term Operating Margin target
0%
5%
10%
15%
20%
25%
30%
35%
40%
201720182019202020212022

Expansion of R&D and manufacturing facilities
NZ 5 – Ground works progressing well on the fifth R&D and
manufacturing facility in Auckland, New Zealand.
~$700m capital expenditure over about five
years. This includes:
New Zealand
•Completion of building 5
•Acquisition of second R&D and
manufacturing campus in New Zealand
Tijuana, Mexico
•Completion of a third manufacturing
facility in Mexico
Future manufacturing
•Additional manufacturing location
outside of New Zealand and Mexico

Andrew Somervell – Vice President
Products and Technology
Better Products:
An R&D Overview

Better Products: Enabling Clinical Practice Change
Requires: New insights, original thoughts,
finding unarticulated need
Improve care
and outcomes
Improve patient
outcomes
Improve the
delivery of care
Lower overall cost
of treating patients
Drive sustainable
profitable growth
Enable treatment
of more patients
Unique
technologies that
deliver customer
valued benefits
Products that:

A Patient Focused Culture
•Underlying philosophy of doing what
is best for patients
−Aligns with long-term needs of all caregivers
• Patient care is complex. Complexity
provides opportunity
• Deep, broad understanding of patient
care leads to new insights and
solutions
•Patient focused, multi-disciplinary
product teams

Patient Focused Teams: In-depth Knowledge

Enabling our Product Teams
•Our people: attracting and growing top
talent
•First-hand access to user environments
•Engaging world-leading expertise
•Leading prototyping and testing
facilities
•Co-locating R&D and manufacturing

Airvo3
Chris Crone – General Manager
Sam Frame – Marketing Manager

Airvo3
Designed to facilitate treatment:
•of more patients
•in more hospital areas
•by more types of clinicians

Integrated battery
Current challenge:
•Nasal high flow requires a
continuous power supply
•Continuity of therapy is key
Airvo3 facilitates:
•Transfer for diagnostics
•Earlier initiation, e.g.prior to
admission

Standardisedtube kits and interfaces
Current challenge:
•Storage and training burden for
new equipment
•Treating a wider range of patients
Airvo3 facilitates:
•A lower barrier to fleet expansion
•Treatment of new patients
requiring smaller interfaces

Option for faster reprocessing
Current challenge:
•Downtime of equipment
•Differing preference of
reprocessing
Airvo3 facilitates:
•Greater time treating patients
•Flexible options for reprocessing

Clinical user menu and settings
Current challenge:
•Distance between decision
makers and patients
•Adherence to hospital protocols
Airvo3 facilitates:
•Personalisedclinical parameters
•Alignment between default
settings and protocols

OptiO
2
-closed loop oxygen control
Current challenge:
•Oxygen can be under or over
delivered
•Difficult to keep patients within
their target range
Airvo3 facilitates:
•Use in areas where control
matters most
•A patient-specific approach

Surgical Humidification
Open Abdominal Surgery
Winston Fong -Vice President
Surgical Technologies

Intro –Laparotomy
•Patient and open surgical
site is exposed to ambient
air during laparotomy
surgery
•Very different to natural
physiological state (warm
and wet)
•Causes evaporation which
results in loss of heat and
moisture from patient

Clinical problems
Hypothermia
Tissue / Cell damage
Surgical site infection

SI400 flow visualisation

Product
SI400Humidified Gas Diffuser
Sterile and
Single use
Adhesive Backing
Mouldable foam head
Low profile
Flexible tube

How could warm, humidified CO
2
benefit the patient?
•Improves temperature
•Provides humidity
•Reduces risk of SSI
•Improves local wound
temperature
•Increases tissue
oxygenation and perfusion
•Reduces morphological
mesothelial damage
CO
2
Warm
Humidity

OptiflowAnesthesia
Winston Fong -Vice President
Surgical Technologies

Optiflownasal high flow therapy
Spontaneously breathing patients
with or at risk of respiratory
compromise
Mechanisms of action
Respiratory
support
Supplemental
oxygen
(if required)
AirwayPatient
comfort hydration
Reduction
of
dead
space
Dynamic
positive
airway
pressure

What is anesthesia?
Amnesia
Controlled state of
unconsciousness and
loss of memory
Analgesia
Management
of pain
Paralysis
Management of
patient movement

General Anesthesia–Clinical complications
•Anestheticagents
−Neuro muscular blockade →
apnoeic
−Loss of muscle tone, airway
collapse, atelectasis
•Complications include
−Airway damage causing:
swelling →airway closure
−Intubation failure
−Desaturation causing anesthetic
morbidity and mortality

Sedation –Clinical complications
•Anestheticagents
−Represses breathing
−Causes atelectasis
•Complications include
−Desaturation: 26-85% of GI
Endoscopy cases desaturate
1
−Disrupts procedure
−Surgery delays
−Patient risk/dissatisfaction
1Nay MA et al. High-flow nasal oxygenation or standard oxygenation for gastrointestinal endoscopy
with sedation in patients at risk of hypoxaemia: a multicentre randomised controlled trial. (2021)

OptiflowSwitch
TM
Enables delivery of humidified oxygen
in the peri-anesthesia environment
User can Switchbetween bag mask
ventilation and Optiflowwithout needing
to remove the nasal interface
Reduces the number of steps required to
bag mask ventilate a patient vs standard
Optiflownasal high flow interfaces

OptiflowTra ce
TM
Continuous sampling of exhaled CO
2
while using
Optiflownasal high flow for oxygenation*
*Attention: this applies for flow rates between 5-50L/min.
Secure connection
with standard CO
2
sampling lines
Sampling of exhaled
gas from either nose
or mouth*

Systematic review
with meta-analysis
Systematic review
Clinical outcome controlledtrial
Physiological/Pilot controlled trial
Observational study/Cohort study
Case report/Case series
Editorial/Commentary/Opinion/Narrative
Benchtop/descriptive study
Guideline
Systematic and growing clinical evidence
2015-2019
2018-2021
2022
Hung, 2022 GI endoscopy – demonstrated the efficacy of
high flow nasal oxygenation for reducing the risk of
hypoxemia in patients under sedation.
Su, 2022 Bronchoscopy - HFNC may provide consistent
oxygenation (SpO
2
>90%) and safer invasive procedures.
Ben-Menachem, 2020 Bronchoscopy - HFNO compared
with LFNO significantly reduces desaturations
Nay, 2021 GI endoscopy - HFNO significantly reduced the
incidence of oxygen desaturation
Lin, 2019 GI endoscopy - HFNC can prevent the incidence of
hypoxia and severe hypoxia undergoing elective gastroscopy
Patel & Nouraei(2015) - NHF is beneficial in extending
apnea time patients with difficult airways undergoing general
anesthesia.

Summary
•Ongoing innovation
•Strong and continually growing clinical evidence
•Change in clinical practice
•Sustainable profitable growth
•Extending the use of Optiflowinto anesthesiapractice

Andrew Somervell – Vice President
Products and Technology
Better Products:
An R&D Overview